Taken together, these data confirm that Met may exert its potential anti-BPH effects by modulating the TGF-β1/Smad2/3 pathway through the inhibition of SOX4, thereby reversing prostate EMT and alleviating fibrosis. Here, TGFB1 is linked to benign prostatic hyperplasia.